PRE-FUNDED COMMON STOCK PURCHASE WARRANT Titan Pharmaceuticals, Inc.Titan Pharmaceuticals Inc • August 8th, 2019 • Biological products, (no disgnostic substances)
Company FiledAugust 8th, 2019 IndustryTHIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Mr. Sunil BhonsleTitan Pharmaceuticals Inc • August 8th, 2019 • Biological products, (no disgnostic substances) • New York
Company FiledAugust 8th, 2019 Industry Jurisdiction
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 8th, 2019 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 8th, 2019 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of August 7, 2019, between Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).